Entero Therapeutics, Inc. (ENTO)
Official siteBIOTECHNOLOGY
Last updated: Nov 13, 2026 at 4:00 PM ET
Entero Therapeutics, Inc. (ENTO) Financials: Revenue, Profit and Cash Flow
Entero Therapeutics reported revenue of $36.25K for the fiscal year ended Dec 31, 2025. That year, net income was -$6.55M with a net margin of -18078.3% and operating cash flow was -$5.70M. The quarter ended Mar 31, 2026 had revenue of $38.21K and net income of -$3.44M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $36.25K | N/A | -1813.6% | -19540.0% | -18078.3% |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.25K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $693.68K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | -$657.43K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $925.48K | $903.94K | $5.03M | $691.26K | $38.32M | $19.14M | $8.68M | $5.77M | $2.40M | $2.50M |
| Operating income | -$7.08M | -$15.62M | -$15.77M | -$12.68M | -$59.06M | -$26.43M | -$14.74M | -$13.43M | -$10.22M | -$6.33M |
| Net income | -$6.55M | -$18.06M | -$15.79M | -$14.63M | -$58.54M | -$32.67M | -$15.18M | -$13.53M | -$11.10M | -$14.59M |
| EBITDA | -$5.21M | -$15.57M | -$15.75M | N/A | -$57.99M | -$25.66M | -$14.16M | -$12.63M | N/A | N/A |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.21K | $36.25K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | -$613.74K | -$657.43K | $0 | $0 | $0 | N/A | $0 | $0 | $0 | -$7.32K | $0 | $0 |
| Operating income | -$3.61M | -$4.69M | -$934.79K | -$638.86K | -$821.39K | -$1.20M | -$1.89M | -$3.43M | -$9.10M | -$4.09M | -$3.43M | -$4.18M |
| Net income | -$3.44M | -$3.14M | -$1.15M | -$998.27K | -$1.26M | -$12.24M | -$2.58M | -$8.81M | $5.57M | -$4.10M | -$3.43M | -$4.19M |
Balance Sheet
As of Dec 2025, short-term debt of $8.28M exceeded cash and equivalents by $7.38M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $48.55M | $85.41M | $6.88M | $5.44M | $11.79M | $12.92M | $8.90M | $7.47M | $5.48M | $6.75M |
| Current assets | $2.60M | $83.48M | $4.96M | $3.41M | $9.42M | $7.87M | $3.41M | $4.80M | $1.95M | $2.96M |
| Cash and equivalents | $899.78K | $163.48K | $3.71M | $1.36M | $8.25M | $6.06M | $175.80K | $1.11M | $573.47K | $1.77M |
| Total liabilities | $19.72M | $27.61M | $3.28M | $2.70M | $19.61M | $15.56M | $4.29M | $3.00M | $3.82M | $3.54M |
| Short-term debt | $8.28M | $0 | $612.78K | $603.49K | $641.24K | $552.40K | $1.52M | $255.03K | $416.55K | $155.19K |
| Shareholder equity | $19.82M | -$3.88M | $3.60M | $2.74M | -$7.82M | -$2.64M | $4.62M | $4.47M | $1.66M | $3.21M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $47.97M | $48.55M | $135.37M | $85.06M | $85.20M | $85.41M | $85.82M | $86.29M | $91.13M | $6.88M | $5.93M | $4.33M |
| Total liabilities | $20.47M | $19.72M | $45.81M | $29.68M | $28.74M | $27.61M | $15.77M | $15.49M | $13.27M | $3.28M | $2.65M | $3.45M |
| Cash and equivalents | $385.54K | $899.78K | $2.52M | $4.47K | $59.35K | $163.48K | $366.79K | $662.48K | $3.43M | $3.71M | $3.29M | $1.24M |
| Shareholder equity | $18.59M | $19.82M | $22.59M | -$6.30M | -$5.22M | $57.80M | $8.37M | $9.12M | $16.18M | $3.60M | $3.28M | $881.96K |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.70M | -$9.22M | -$12.38M | -$22.34M | -$32.29M | -$11.22M | -$14.03M | -$10.87M | -$7.18M | -$4.53M |
| Capital expenditures | N/A | $0 | $500.00K | $0 | $69.49K | $4.17K | $24.10K | $305.47K | $32.17K | $12.36K |
| Free cash flow | N/A | -$9.22M | -$12.88M | -$22.34M | -$32.36M | -$11.23M | -$14.06M | -$11.17M | -$7.22M | -$4.55M |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.42M |
| Investing cash flow | $323.48K | $88.17K | -$500.00K | $0 | -$10.32M | $87.35K | -$24.10K | -$305.47K | -$32.17K | -$12.36K |
| Financing cash flow | $5.89M | $5.58M | $15.23M | $15.74M | $44.76M | $17.05M | $13.14M | $11.71M | $6.01M | $5.75M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.79M | -$3.97M | -$855.69K | -$54.88K | -$818.63K | -$171.52K | -$1.85M | -$3.45M | -$3.75M | -$3.44M | -$3.33M | -$2.76M |
| Capital expenditures | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $4 | $500.00K | $0 | $0 |
| Free cash flow | N/A | N/A | -$855.69K | -$54.88K | -$818.63K | -$171.52K | -$1.85M | -$3.45M | -$3.75M | -$3.94M | -$3.33M | -$2.76M |
Frequently Asked Questions About ENTO
What is Entero Therapeutics' annual revenue?
Entero Therapeutics reported revenue of $36.25K for the fiscal year ended Dec 31, 2025.
Is Entero Therapeutics profitable?
No. Entero Therapeutics reported net income of -$6.55M for the fiscal year ended Dec 31, 2025, with a net margin of -18078.3%.
How much debt does Entero Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $8.28M and cash and equivalents of $899.78K.
What is ENTO's profit margin?
For the fiscal year ended Dec 31, 2025, Entero Therapeutics reported gross margin of -1813.6%, operating margin of -19540.0% and net margin of -18078.3%.
ENTO pages: Overview, Financials